Plein Center Assistant Director, Zach Marcum, PharmD, PhD, served as co-first author on a paper published in Neurology, along with Plein Center Director, Shelly Gray, PharmD, MS, and Plein Center faculty member, Douglas Barthold, PhD, which compared different antihypertensive sub-classes in their association with incidence of dementia using data from a Dutch trial of dementia prevention. In this paper, investigators from the University of Amsterdam and the University of Washington found that users of thiazides, dihydropyridine calcium channel blockers, and angiotensin-I receptor blockers had a significantly lower dementia rates compared to users of angiotensin-converting enzyme inhibitors, beta blockers, and non-dihydropyridine calcium channel blockers. This paper was presented at the 2020 American Geriatrics Society Annual Meeting’s Plenary Session.